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a  b  s  t  r  a  c  t
We  analyzed the 124 deaths reported in Portugal form ﬂu pandemic. The estimated mortality
rate was 1.17/100 000 population. 60% were males, the average age was 47.6 and 66.1% had
at  least one risk factor. Chronic lung and heart diseases were the most common risk factors.
Viral pneumonia was the major cause of death. 11% of the deceased had no treatment
with neuraminidase inhibitors and none was vaccinated against the pandemic strain of ﬂu.
Compared to average life expectancy, we estimated that 3859 years of potential life were
lost.
In  the future, we should work on improved strategies for risk communication for health
professionals and general public.
© 2012 Escola Nacional de Saúde Pública. Published by Elsevier España, S.L. All rights
reserved.
Relatório  ﬁnal  sobre  a  mortalidade  na  pandemia  de  gripe  (H1N1)  de  2009
em  Portugal  (de  abril  de  2009  a  agosto  de  2010)
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nos potenciais de vida perdidos
r  e  s  u  m  o
Em Portugal, durante a pandemia de gripe A(H1N1) 2009 foram reportados 124 óbitos. A taxa
de  mortalidade estimada foi de 1,17/100 000 habitantes. 60% dos falecidos eram do sexo
masculino, a média das idades foi de 47,6 anos e em 66,1% havia pelo menos um factor de
risco.  As doenc¸as crónicas respiratórias e cardíacas foram os factores de risco mais comuns.
A  pneumonia viral primária foi a principal causa de morte. 11% dos falecidos não receberam
terapêutica com antivíricos e nenhum foi vacinado com a vacina pandémica. Em relac¸ão àesperanc¸a  média de vida, os anos potenciais de vida perdidos foram 3859 anos.No  futuro em circun
comunicac¸ão  do risco par
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Um relatório preliminar deste estudo foi publicado na Revista
Portuguesa de Medicina Intensiva (Rev Port Med Int 2010;
17(4):11–19).
A preliminar report of this study has been published in Revista
Portuguesa de Medicina Intensiva (Rev Port Med Int 2010;
17(4):11–19).
This report is dedicated to the families of victims of pandemic
inﬂuenza.
Introduction
Portugal activated their Contingency Plan1 for the ﬂu pan-
demic on 24 April 2009 and it remained in force until 21 August
2009. The ﬁrst case notiﬁed in the country was diagnosed on
29 April 2009.
As in other countries in Portugal all deaths associated with
Flu A (H1N1) 2009 were reported. Throughout the pandemic
only related deaths were mandatory to be registered. From the
start of the Contingency Plan through to the end of the pan-
demic, which was ofﬁcially declared over by the World Health
Organization (WHO) on 10 August 2010, there were 124 deaths.
The ﬁrst occurred on 23 September 2009 and the last on 3
March 2010. The results of our analysis of reported deaths in
Portugal from the ﬂu pandemic have a great deal to contribute
to our understanding of the characteristics of infection from
the ﬂu virus A (H1N1) 2009, and can help to improve standards
of preparation for future pandemics.
Objectives
To make a thorough examination of the deaths from the ﬂu
pandemic according to sex, age group, risk factors from severe
disease, hospital admission, length of hospital stay, causes of
death, antivirus treatment, vaccination status and the esti-
mated mortality rate and years of expected life lost.
Materials  and  methods
All deaths were conﬁrmed by laboratory tests using RT-PCR.
We analyzed the data from the database of the Directorate-
General for Health (Direc¸ão-Geral da Saúde [DGS]) of the
Ministry of Health, which was subsequently validated by tele-
phone, email or by visits from representatives of DGS to the
hospitals.
The following were considered severe risk factors in the
context of ﬂu pandemic (H1N1) 20092:
1. No risk factors
2. Pregnancy/postpartum (≤15 days after birth)
3. Chronic lung disease (e.g. asthma, COPD, cystic ﬁbrosis)
4. Chronic kidney disease
5. Chronic heart disease (excluding isolated Arterial Hyper-
tension)
6. Chronic liver disease
7. Chronic hematologic disease (e.g. hemoglobinopathies,excluding oncological disorders)
8. Neurological disease/chronic neuromuscular disease
9. Chronic metabolic disease (e.g. diabetes) a . 2 0 1 4;3 2(1):55–60
10. Cancer (e.g. solid and haematological tumours)
11. Immunosuppression (e.g. congenital, associated with HIV
and organ transplant, post-chemotherapy, immunother-
apy, steroids at immunosuppressant levels.)
12. Morbid obesity (<10 years old: IMC ≥25; ≥10 and <18 years
old: IMC ≥35; ≥18 years old: IMC ≥40)
13. Chronic therapy with salicylates in patients aged
<18 years
The following were considered as causes of death:
1. Viral infection, including primary viral pneumonia and
other causes of viral infection (e.g. encephalitis or myoperi-
carditis)
2. Secondary bacterial pneumonia (concurrent or as a result
of viral infection and not contracted in hospital)
3. Decompensation due to comorbidity
4. Complications or intercurrent disease during hospital-
ization (e.g. haemorrhage, stroke, pulmonary embolism,
barotraumas, nosocomial infections)
Figures from the Institute of National Statistics for the Por-
tuguese population on 31/12/20083 were used to calculate the
mortality rate. To calculate the expected years of life lost,
the age of each individual at the time of death was subtracted
from the average life expectancy at birth in Portugal for the
three-year period 2007–2009, speciﬁed by sex.4–7 The number
of years of potential life lost per 100 000 population was calcu-
lated by dividing the total number of years lost by the estimate
of the Portuguese population younger than the average life
expectancy.
To analyze the data we  used PASW Statistics® version 18
and Microsoft Excel 2003. The comparison of the mean age was
calculated using the p value of Student’s t test and ANOVA. We
considered all non-signiﬁcant differences in those where the
p-value was greater than 0.05.
Results
In Portugal 124 deaths caused by the ﬂu pandemic were
reported. With the exception of one death which occurred at
home, all the patients (123: 99.2%) died in National Health
Service hospitals. The death toll represents a mortality rate
of 1.17 per 100 000 population. There were no deaths among
health professionals.
Age  and  sex
There were 74 male deaths (59.7%) and 50 female (40.3%). The
average age of death was 47.6 and the median age 49, there
was no statistically signiﬁcant difference (p = 0.873) between
the sexes, the average and median ages were 47.9 and 50 for
males and 47.3 and 47 for females, respectively. The youngesthalf the deaths (46.8%) happened between the ages of 45 and
64 and around 1⁄3 (35.5%) were between the ages of 15
and 44. Only 16 (12.9%) deaths occurred in the age group ≥65
(Table 1).
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Table 1 – Distribution of deaths from ﬂu pandemic
(H1N1) 2009 according to age group, sex and mortality
rate per 100 000 population, from April 2009 to August
2010, Portugal.
Age group and sex No. (%) Mortality
rate/105
population
Age group
00–04 years 2 (1.6) 0.38
05–14 years 4 (3.2) 0.37
15–64 years 102 (82.3) 1.43
15–44 years 44 (35.5) 1.00
45–64 years 58 (46.8) 2.13
≥65 years 16 (12.9) 0.85
Sex
Male 74 (59.7) 1.44
Female 50 (40.3) 0.91
Total 124 (100) 1.17
Source: DGS.
Table 2 – Number and percentage of deaths from ﬂu
pandemic (H1N1) 2009, according to risk factor,
from April 2009 to August 2010, in Portugal.
Risk factors No. (%)
Chronic lung disease 20 (24.4)
Chronic heart disease 17 (20.7)
Immunosuppression 16 (19.5)
Chronic metabolic disease 15 (18.3)
Cancer 14 (17.1)
Neurological disease/chronic
neuromuscular disease
14  (17.1)
Chronic liver disease 11 (13.4)
Morbid obesity 8 (9.8)
Chronic kidney disease 4 (4.9)
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Table 3 – Number and percentage (in descending order)
of deaths from ﬂu pandemic (H1N1) 2009, according to
the cause of death; the total and the presence or absence
of risk factors, from April 2009 to August 2010, Portugal.
Cause of death Total no. (%) Without
risk factors
With risk
factors
Viral infection 102 (82.2) 37 (88.1) 65 (79.2)
Primary viral
pneumonia
99 (79.8) 35 (83.3) 64 (78.0)
Encephalitis
and/or
myopericardi-
tis
3 (2.4) 2 (4.8) 1 (1.2)
Complication/
intercurrent
disease
10 (8.1) 5 (11.9) 5 (6.1)
Decompensation
from
comorbidity
8 (6.5) 0 (0) 8  (9.8)
Secondary
bacterial
pneumonia
4 (3.2) 0 (0) 4 (4.9)
The most common cause of death in the 7 children aged <18Pregnancy/post-partum 1 (1.2)
Source: DGS.
isk  factors
f the 124 deaths, 82 (66.1%) had at least one risk factor for seri-
us disease. The average age for these patients was 48.5, which
as higher than the 46.0 for those who had no risk factor
n = 42; 33.9%), but without statistical signiﬁcance (p = 0.471).
Of the 82 patients with risk factors, 52 (63.4%) had only one
isk factor and 30 (36.6%) had more  than one risk factor. Of the
 (7.3%) cases that had 3 or more  risk factors all of them were
ver 45. Among the paediatric cases (aged <18), 6 (85.7%) of
he 7 who  died had, at least, 1 risk factor. The presence of risk
actors was 68.8% in the age group ≥65 and was lowest (56.8%)
mong the age group 15–44.
Lung disease and chronic heart disease were the most
ommon risk factors identiﬁed in respectively 20 (24.4%) and
7 (20.7%) patients, followed by immunosuppression in 16
19.5%) cases (Table 2). Among the paediatric patients the most
ommon risk factor was neuromuscular disease, which was
resent in 4 (66.7%) of the 6 children who  had risk factors.
Obesity classes I and II (IMC: ≥30 and <40) were not consid-
red a risk factor. However, it was mentioned in 18 cases, 12 ofTotal 124 (100) 42 (100) 82 (100)
Source: DGS.
which had no risk factor. In the group with chronic metabolic
diseases only one suffered from diabetes mellitus. Of  the
14 cases with chronic neurological/neuromuscular disease,
three had Down’s syndrome.
Admission  to  hospital  and  to  ICU
Of 124 deaths, 123 (99.2%) occurred in National Health Service
hospitals. The other death happened at home. The average
length of internment for those who died was 15.0 days, the
median was 11, the maximum was 68 and the minimum 0
days. The average length of internment was 5.2 days for chil-
dren <18 years, 15.5 days for patients between 18 and 64 years
and 17.1 days for those ≥65. For patients with no risk factor
the average length of internment was 19.9 days and for those
with risk factors it was 13.0 days.
Of the 123 patients hospitalized, 95 (77.2%) were treated in
Intensive Care Units. 94 (98.9%) of these patients were treated
with invasive mechanical ventilation. Three of the patients
also had ECMO (Extra Corporeal Membrane Oxygenation) out of a
total of 6 patients who have been treated with this procedure
in Portugal during ﬂu pandemic.
Cause  of  death
Primary viral pneumonia diagnosed in 99 (79.8%) of the
124 patients, was the most common cause of death, followed
by complications/intercurrent disease while in hospital and
decompensation caused by comorbidity, which occurred in 8.1
and 6.5% of cases respectively. Secondary bacterial pneumonia
was diagnosed in only 4 (3.2%) cases (Table 3).was primary viral pneumonia in 6 cases (85.7%). In the other
case the cause of death was decompensation from chronic
respiratory disease.
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Neuraminidase  inhibitor  therapy
In 6 cases out of the 124 deaths it is not known if they were
treated with neuraminidase inhibitors. We  do know that it was
used with 105 patients (89.0%), but it was not possible to estab-
lish the length of time between the onset of symptoms and
starting the therapy. They were all given oseltamivir, and 3
were also given zanamivir intravenously. 13 (11.0%) patients
had no antivirus therapy; 7 of these died in the ﬁrst 24 h after
admission and in 9 cases laboratory conﬁrmation of disease
(RT-PCR) was post-mortem.
Vaccination  status
82 (66.1%) of the patients had risk factors and therefore should
have been vaccinated. One of the patients contracted the dis-
ease in the ﬁrst week after being vaccinated and two, with
serious immunosuppression (hematologic malignancy) had
fallen ill in the interval between the 1st and 2nd vaccines.
None of the other 79 who had risk factors had been vacci-
nated. In 64 of these cases it was possible to work out how
long it would have been between the date they were admitted
to hospital and the completion of the vaccination scheme, if
they had been vaccinated according to guidelines for groups
at risk, according to the schedule of national vaccinations.
The length of time was as follows:
- for 29 (45.3%), more  than or equal to 4 weeks;
- for 5 (7.8%), more  than 3 weeks but less than 4;
- for 30 (46.9%), less than 3 weeks.
Potential  years  of  life  lost
3859 was the estimated ﬁgure for the number of potential
years of life lost, which is equivalent to 40.0 years per 100 000
population. The average number of potential years of life lost
for each person who  died was 31.
Discussion
In Portugal notiﬁcation of death from ﬂu pandemic was
mandatory. This study covers the 124 reported deaths which
were conﬁrmed by laboratory tests RT-PCR. However, we  must
accept that there might have been other deaths, where this
diagnosis was not considered and so patients were not tested
or cases of false negative results due to technical problems in
sample collection or problems with the quality of laboratory
testing. Despite these possible limitations, which would have
also been true of other studies of the same kind, we are conﬁ-
dent that the DGS database is reliable and if it does not cover
all, it does include the great majority of the deaths in Portugal.
It is the ﬁrst time in a ﬂu pandemic that only the death toll,
conﬁrmed by laboratory tests, has been recorded, which may
help to explain discrepancies in comparisons with the impact
of earlier pandemics. It should also be noted that laboratory
testing for conﬁrmation is not used to assess the mortality rate
during annual epidemics of seasonal ﬂu.
These 124 deaths represent a mortality rate of 1.17/100 000
population, about a third of the estimate of the ECDC (up a . 2 0 1 4;3 2(1):55–60
to 3 per 100 000 population) in its “reasonable worst case
scenario”.8 This speciﬁc mortality rate, although higher than
the average for countries in the European Union,9 is within the
reference ranges for this region, and it is also higher than
the estimates for the United States (USA) of 0.97/100 000.10
Without knowing the exact number of patients who were
affected and symptomatic we cannot establish an overall case
fatality rate or the case fatality rate for symptomatic illness.
In the USA11 and United Kingdom,12 the case fatality rate for
symptomatic illness has been estimated at 0.048% and 0.026%,
respectively.
The average age of patients who died was 47.6, with a slight
predominance of males (59.7%); there was no signiﬁcant differ-
ence in average ages of the sexes. The age group most affected
was 15–64, in particular the subgroup between 45 and 64 which
had a mortality rate of 2.13/100 000 population. The overrepre-
sentation of males was noted in other European countries, for
example France13 (57%) and Holland14 (55%). The fact that it
affected younger age groups is also in line with other studies,
the average age at death in the United Kingdom15 was 43 and
it was 52 in Holland.14
In Portugal, 87.1% of deaths happened in the under 65s,
which corroborated the global estimate that approximately
90% of those who died were under 65.16 This contrasts signiﬁ-
cantly with ﬁgures for seasonal ﬂu in this country, where more
than 80% of deaths occur in people who are 75 and over.17
25–50% of those who died were estimated to have no risk
factors for the ﬂu pandemic.16 In Portugal 33.3% of deaths
occurred in people with no risk factor; in United Kingdom
it was 23%.15 Although the values found in our country are
within the reference ranges, the variations found could have
been partially inﬂuenced by the fact that the methodologies
used were not uniform and different weight was given to
some of the risk factors, for example, obesity. In this analy-
sis morbid obesity (BMI ≥ 40 in adults and the corresponding
value for patients <18 years) was considered a risk factor. If
non-morbid obesity is also included (IMC ≥ 30 in adults with a
corresponding value for children) means that there were only
23.6% patients without a risk factor.
The distribution of risk factors that were found in the Por-
tuguese population is very much the same as the international
picture with the exception of pregnancy/post-partum. Only
one patient in Portugal died in these circumstances (0.8% of
total deaths), whereas the values described in the literature
in other countries were between 6% and 9%.18,19 In our study
it was not possible to come to any conclusions about this dif-
ference. Only one (14.3%) of the children did not have a risk
factor and almost half (43.2%) of the deaths between 15 and
44 years did not present risk factors. In the United Kingdom,
it was also among those between 25 and 44 years of age that
there was the highest percentage (32%) of deaths without risk
factors.15
Diffuse viral pneumonitis was the most common cause of
death (79.8%), which was independent of age group or the
existence of risk factors. This very high percentage of cases
of primary viral pneumonia, usually associated with ARDS
(Acute Respiratory Distress Syndrome), severe hypoxaemia, septic
shock and kidney failure, matches what is described in other
studies, for example in Australia18 and Canada19 and probably
explains why so many  of the patients were put on mechanical
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entilation and had complications and intercurrent diseases
8.1%). Throughout the period of the pandemic although there
as often a considerable delay before hospital admission there
ere no reports of shortage of hospital beds in the ICUs.
Data from other studies indicate percentages of 26–38% for
eaths from bacterial pneumonia,18–21 whereas here accord-
ng to our data it was only 3.2%; we  did not have enough
nformation to explain this disparity, but it could be related
o the effectiveness of the diagnosis by microbiological testing
nd antibiotic treatment prior to the collection of samples.
In 11.0% of deaths there had been no speciﬁc treatment
ith neuraminidase inhibitors. In a similar study in South
orea this percentage was 13%22 and 24% for patients who
ied in hospital in the USA in September and October 2009.23
n our series, even though the majority died in the ﬁrst 24 h
f hospitalization, the delay in starting antiviral treatment in
he serious cases, because of, for example, waiting for conﬁr-
ation of the results of laboratory tests, can be considered
 breach of the national technical guidelines issued by the
GS.
In addition, for the ﬁrst time in the history of pandemics,
here was a vaccine available. In Portugal a pandemic vaccine
ith an adjuvant (Pandemrix)  was available from 26 October
009 according to a schedule set down  according to risk fac-
ors. None of the people who  died had been vaccinated for
andemic ﬂu, not even those whose risk factors should have
ade them a priority. In a study of 25 adults aged between 20
nd 48 who were given a vaccine similar to the one available
n Portugal, the levels of seroconversion were 78% and 88% at
4 and 21 days, respectively.24 In our study more  than 40% of
hose with a risk factor and who died could have been vacci-
ated in time to prevent serious illness or death, but this did
ot happen. On the contrary the national technical guidelines
ere not respected and there was a lack of communication
nd proper understanding of the risks involved on the part of
ealth professionals and the general public.
Using estimates as a base for potential years of life lost
llows us to have a different perspective on the implications
f the pattern of death which we  do not get by just looking
t the numbers of deaths, in isolation.25 In this way we can
ee that in Portugal the number of potential years of life lost
as 3859 years, which corresponds to 40.0 years per 100 000
opulation, giving us a clearer picture of the effect of the 124
egistered deaths.
onclusion
he mortality rates in Portugal were in general comparable to
hose found in other developed countries. However in future
rises the Public Health Services should be prepared to impose
andatory reporting for all the most serious cases, for exam-
le admission to a hospital ward or to an ICU, which would
e in line with best practice in epidemiology, both clinical
nd resource management. Equally there should be measures
n place to improve risk communication strategies for health
rofessionals and the general public. An analysis of potential
ears of life lost, because it shows the impact of death in real
erms rather than looking at the bald number of actual deaths,
ives more  insight into the effect of these deaths, and for this
1 . 2 0 1 4;3  2(1):55–60 59
reason should be included wherever possible in the evaluation
of the effect of illness that can be classed as pandemics.
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